



(12) Translation of
European patent specification

(11) NO/EP 3464318 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 39/00 (2006.01)
A61K 47/68 (2017.01)
A61P 37/06 (2006.01)
C07J 71/00 (2006.01)
C07K 16/18 (2006.01)
C07K 16/24 (2006.01)

Norwegian Industrial Property Office

(45) Translation Published 2021.08.16

(80) Date of The European
Patent Office Publication of
the Granted Patent 2021.04.21

(86) European Application Nr. 17733222.8

(86) European Filing Date 2017.06.01

(87) The European Application's
Publication Date 2019.04.10

(30) Priority 2016.06.02, US, 201662344948 P
2016.08.04, US, 201662371134 P

(84) Designated Contracting
States: AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ;
IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ;
SK ; SM ; TR

Designated Extension
States: BA ; ME

(73) Proprietor AbbVie Inc., 1 North Waukegan Road, North Chicago, IL 60064, USA

(72) Inventor MCPHERSON, Michael J., 287 Pillsbury Road, AshbyMassachusetts 01431, USA
HOBSON, Adrian D., 25 Holman Street, ShrewsburyMassachusetts 01545, USA
HAYES, Martin E., 3 Celestial Way, PepperellMassachusetts 01463, USA
MARVIN, Christopher C., 242 Braxton Way, GrayslakeIllinois 60030, USA
SCHMIDT, Diana, 40606 South Sunset Drive, AntiochIllinois 60002, USA
WAEGELL, Wendy, 7 Rice Corner Road, BrookfieldMassachusetts 01506, USA
GOESS, Christian, 112 Mashapaug Road, SturbridgeMassachusetts 01566, USA
OH, Jason Z., 61 Beverly Hill Drive, ShrewsburyMassachusetts 01545, USA
HERNANDEZ JR., Axel, 14 Laurie Lane, CharltonMassachusetts 01507, USA
RANDOLPH, John T., 304 Broadway Avenue, LibertyvilleIllinois 60048, USA

(74) Agent or Attorney CURO AS, Vestre Rosten 81, 7075 TILLER, Norge

(54) Title **GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF**


(56) References
Cited: WO-A1-2014/152247
WO-A2-2009/069032
WO-A1-01/94585

WO-A1-2015/153401
WO-A2-2007/117685

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Forbindelse:



hvor n er 2 eller 4, og A er et antistoff som omfatter SEQ ID NO: 66 og SEQ ID NO:73 eller
 5 adalimumab.

2. Forbindelse ifølge krav 1, hvor n er 4.

3. Forbindelse ifølge krav 1, hvor n er 2.

4. Forbindelse ifølge krav 2 eller krav 3, hvor A er adalimumab.